Mutagenesis vol. 18 no. 4 pp. 345-353,
July 2003
© 2003 UK Environmental Mutagen Society/Oxford University Press
Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity
Genetic Toxicology, GlaxoSmithKline, Park Road, Ware SG12 0DP, UK
Although the application of the concept of a threshold to risk assessment is widespread, there remains little experimental evidence for the existence of thresholds for genotoxic compounds, other than aneugens. The clastogenicity of topoisomerase inhibitors is believed to result from the transient stabilization of the topoisomerase enzyme with DNA during the catalytic cycle. This leads to the formation of a stabilized cleavage complex, which, in turn, may result in the formation of a DNA strand break. This indirect mechanism of clastogenicity is the basis for the concept of threshold for this class of drug. Using micronucleus induction in L5178Y mouse lymphoma cells as a genotoxic end-point, a three pronged approach was used to examine whether the concept of a threshold for clastogenicity could be demonstrated for topoisomerase type II inhibitors in vitro. This involved (i) the study of mechanism (TARDIS assay), (ii) hypothesis testing versus estimation (i.e. scoring up to 10 000 cells/treatment at concentrations immediately above and below the NOEL for micronucleus induction) and (iii) statistical modelling of the concentration–response curves for micronucleus induction. Several topoisomerase type II inhibitors were investigated with varying clastogenic potencies (etoposide = doxorubicin < genistein < ciprofloxacin). Pragmatic thresholds for clastogenicity in L5178Y cells were defined at 0.00236 µg/ml for etoposide, 0.00151 µg/ml for doxorubicin, 1 µg/ml for genistein and 50 µg/ml for ciprofloxacin. In addition, it was demonstrated that etoposide-induced clastogenicity was concentration and time dependent. These results, along with mechanistic data showing that all of the compounds induced concentration-dependent increases in the formation of topoisomerase II stabilized cleavage complexes, provide a weight of evidence to support a threshold concept for clastogenicity with topoisomerase II poisons.
1To whom correspondence should be addressed. Email. anthony_m_lynch{at}gsk.com
Received on December 5, 2002 revised and accepted on March 13, 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Kirkland, M Aardema, N Banduhn, P Carmichael, R Fautz, J-R Meunier, and S Pfuhler In vitro approaches to develop weight of evidence (WoE) and mode of action (MoA) discussions with positive in vitro genotoxicity results Mutagenesis, May 1, 2007; 22(3): 161 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Doak, G. J.S. Jenkins, G. E. Johnson, E. Quick, E. M. Parry, and J. M. Parry Mechanistic Influences for Mutation Induction Curves after Exposure to DNA-Reactive Carcinogens Cancer Res., April 15, 2007; 67(8): 3904 - 3911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Tebbi, W. B. London, D. Friedman, D. Villaluna, P. A. De Alarcon, L. S. Constine, N. P. Mendenhall, R. Sposto, A. Chauvenet, and C. L. Schwartz Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease J. Clin. Oncol., February 10, 2007; 25(5): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Moore, Y. Wang, W. G. Stebbins, D. Gao, X. Zhou, R. Phelps, M. Lebwohl, and H. Wei Photoprotective effect of isoflavone genistein on ultraviolet B-induced pyrimidine dimer formation and PCNA expression in human reconstituted skin and its implications in dermatology and prevention of cutaneous carcinogenesis Carcinogenesis, August 1, 2006; 27(8): 1627 - 1635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Maralhas, A. Monteiro, C. Martins, M. Kranendonk, A. Laires, J. Rueff, and A. S. Rodrigues Genotoxicity and endoreduplication inducing activity of the food flavouring eugenol Mutagenesis, May 1, 2006; 21(3): 199 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Asano, D. K. Torous, C. R. Tometsko, S. D. Dertinger, T. Morita, and M. Hayashi Practical threshold for micronucleated reticulocyte induction observed for low doses of mitomycin C, Ara-C and colchicine Mutagenesis, January 1, 2006; 21(1): 15 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.J.S. Jenkins, S.H. Doak, G.E. Johnson, E. Quick, E.M. Waters, and J.M. Parry Do dose response thresholds exist for genotoxic alkylating agents? Mutagenesis, November 1, 2005; 20(6): 389 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fukushima, A. Kinoshita, R. Puatanachokchai, M. Kushida, H. Wanibuchi, and K. Morimura Hormesis and dose-response-mediated mechanisms in carcinogenesis: evidence for a threshold in carcinogenicity of non-genotoxic carcinogens Carcinogenesis, November 1, 2005; 26(11): 1835 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Bolt and G. H. Degen Human Carcinogenic Risk Evaluation, Part II: Contributions of the EUROTOX Specialty Section for Carcinogenesis Toxicol. Sci., September 1, 2004; 81(1): 3 - 6. [Abstract] [Full Text] [PDF]
|
|